Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Roivant Sciences, with 10 buy ratings, one strong buy, one hold and one sell. The average 12-month price target is $40.63, while Guggenheim and TD Cowen recently raised their targets to $46 and $55, respectively.
• Roivant shares opened at $40.82, near their 12-month high of $42.50, and are trading above both their 50-day and 200-day moving averages. The company beat quarterly EPS estimates by $0.04 but reported revenue below expectations.
• Insiders have been net sellers, selling more than 3.05 million shares worth approximately $107.3 million over the past 90 days; insiders own 8.8% of the company. Hedge funds and other institutions hold 64.76% of outstanding shares.

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the thirteen analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $40.6250.

ROIV has been the subject of several research reports. Guggenheim upped their target price on Roivant Sciences from $42.00 to $46.00 and gave the stock a "buy" rating in a research note on Wednesday. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a report on Tuesday, August 25th. Bank of America restated a "neutral" rating on shares of Roivant Sciences in a report on Friday, July 31st. TD Cowen upped their price objective on shares of Roivant Sciences from $50.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Sanford C. Bernstein raised shares of Roivant Sciences to a "strong-buy" rating in a report on Wednesday, July 29th.

Roivant Sciences Stock Down 0.3%

Shares of ROIV stock opened at $40.82 on Friday. The business has a 50-day moving average price of $35.79 and a two-hundred day moving average price of $31.62. Roivant Sciences has a 12-month low of $13.81 and a 12-month high of $42.50. The firm has a market cap of $29.49 billion, a P/E ratio of -77.02 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, research analysts expect that Roivant Sciences will post -2 EPS for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other news, insider Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $36.48, for a total value of $5,280,698.88. Following the transaction, the insider owned 18,630,739 shares in the company, valued at approximately $679,649,358.72. The trade was a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel Gold sold 12,380 shares of the business's stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total value of $436,766.40. Following the completion of the sale, the director directly owned 13,689,166 shares of the company's stock, valued at approximately $482,953,776.48. This trade represents a 0.09% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,055,913 shares of company stock valued at $107,261,258. Corporate insiders own 8.80% of the company's stock.

Hedge Funds Weigh In On Roivant Sciences

A number of large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its position in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company's stock valued at $24,553,000 after purchasing an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Roivant Sciences by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company's stock worth $24,678,000 after buying an additional 34,341 shares during the period. American Century Companies Inc. increased its stake in shares of Roivant Sciences by 1.9% in the second quarter. American Century Companies Inc. now owns 89,625 shares of the company's stock worth $1,010,000 after buying an additional 1,689 shares during the period. Russell Investments Group Ltd. raised its holdings in Roivant Sciences by 149.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company's stock valued at $129,000 after buying an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp raised its holdings in Roivant Sciences by 10.2% during the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company's stock valued at $144,000 after buying an additional 1,181 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.